Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whitewater55,
The Cambridge Sign Compagny did something similar for Bicycle Therapeutics (Elaine Dowell).
Bicycle Therapeutics - plc Babraham Research Campus = next Sawston.
https://scontent-bru2-1.xx.fbcdn.net/v/t1.0-9/23722211_754125811451899_5979172332296784849_n.jpg?_nc_cat=103&_nc_oc=AQlgKN8l2sK9zgqa42xbQh2f2LAxH_y8BwkKVmIasNWXflkKVh2EU0gP9UZGAe0eSySU_nz-li4aprHjtVqu4W5N&_nc_ht=scontent-bru2-1.xx&oh=0d71e1d5fc3db90e179299128d996bee&oe=5DF2617F
Two 6,5m signs installed: one Advent Bioservices and one Northwest Biotherapeutics.
The Cambridge Sign Compagny.
Facebook (https://www.facebook.com/TheCambridgeSignCompany/) :
Aug.16, 2019
Two 6.5m signs installed at high level for Advent Bioservices today, Sawston.
https://scontent-bru2-1.xx.fbcdn.net/v/t1.0-9/67975689_1136892459841897_8587993829422923776_n.jpg?_nc_cat=107&_nc_oc=AQnm7h46Lpd1l4jaYak8-xfI7vY3dWS9hAV9pRmpDwMbnQNDPodP3wDKKjZ_9fagVM7v19AVEjMA3dHVnW6w_8Iw&_nc_ht=scontent-bru2-1.xx&oh=3a66222dd34efdf45d231cc0ebd20c94&oe=5E3B2DBC
Thanks Flipper! I look forward to the next PR.
Cognate BioServices: https://www.cognatebioservices.com/
Welcome to Cognate BioServices, Your CDMO Commercialization Partner.
UK
Investment into manufacturing capability; 1,185,000 sq/ft announced. (between Dec 2018 - Sept 2019)
Advent Bioservices; 81,000 sq/ft Announced Jan.2019
https://www.linkedin.com/in/paulhheath/detail/recent-activity/
Smith on Stocks:
Nearly 1 million Belgians donated money for a baby to receive lifesaving gene therapy.
— New York Daily News (@NYDailyNews) September 19, 2019
The drug is not available in Europe, forcing the parents to travel to the U.S. and pay $2.1 million, the full price of the treatment. https://t.co/LSkq9PI8C3
Sentiment,
Laura Nuttall heads back to uni 10 months after being diagnosed with brain tumours.
https://www.lancashiretelegraph.co.uk/news/17906988.laura-nuttall-heads-back-uni-10-months-diagnosed-brain-tumours/?ref=twtrec
"Some personal anecdotes."(Linda Liau)
White Coat Ceremony
UCLA David Geffen School of Medicine
August 9, 2019 Keynote Speaker - Dr. Linda M. Liau, M.D., Ph.D. ,MBA Professor and Chair Department of Neurosurgery.
Sentiment,
I have my doubts about the correct disclosure of the facts in the first article.
Read this:
Jamil Newirth Aug.09, 2012
Hey Google Group,
Thank you all for your concern, thoughts and prayers. I was scheduled for surgery at UCSF yesterday but I canceled last minute and I am now at UCLA with surgery tomorrow morning. It was a difficult decision because UCSF has the best surgeons but ucla is offering a DCVax clinical trial I really want to participate in. Just keep thinking good thoughts if you can and I hope to beat this and be back on track asap. Hope all is well with everyone. All the best.
Take care,
Jamil Newirth
https://groups.google.com/forum/#!topic/ggulsn-3/Yb2TImyVsBY
Dr Bala,
Thank you for that article "Cancer Drug News". (June 05, 2019 Fitch Solutions)
Fitch Solutions store: Advances In Cancer Immunotherapy.
Profiles of the Key Companies To Watch:
• Advaxis, Affimed, Five Prime Therapeutics, Immatics, Immutep, Incyte, Inovio, Medigene, NewLink Genetics, Northwest Biotherapeutics.
https://store.fitchsolutions.com/pharmaceuticals-healthcare/advances-in-cancer-immunot
Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.
Liang Yen Liu,‡,1 Matthew S Ji,‡,1 Nhung T Nguyen,‡,1 Frances E Chow,1 Donna M Molaie,1 Sean T Pianka,1Richard M Green,2 Linda M Liau,3 Benjamin M Ellingson,4 Phioanh L Nghiemphu,1 Timothy F Cloughesy,1 andAlbert Lai*,1
Published online 2019 Jul 11. doi: 10.2217/cns-2019-0007
Abstract.
Aim:
Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS).
Patients & methods:
We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients.
Results:
Among 962 grade-IV, 221 grade III, and 214 grade II Bev-treated glioma patients, we identified 28 (2.9%), 14 (6.3%) and 8 (3.7%) Bev-LTS patients, respectively. 45 Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy.
Conclusion:
Our study shows that a small portion of grade-IV, -III, and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713025/
Martino Sclavi - update Aug.31, 2019.
Biosectinvestor,
I agree, especially if you connect it with this earlier post about Dr. Furberg and IMMUNICUM AB (Sentiment stocks post 213509 - 02/07/19).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146672036
Gary,
Dcvax-L is available but only through te UK Specials programme.
https://brainstrust.org.uk/wp-content/uploads/2019/03/brainstrust-know-hows-immunotherapy-10.02.19-1.pdf
Evaluate,
That is correct. See this:
https://investorshub.advfn.com/uimage/uploads/2019/3/19/TPQGGVAUVTAMWVKZXBYKPUBR.JPG
Sukus,
IMMUNOSCORE® - JÉRÔME GALON - LINDA POWERS - NWBO
June 13, 2016
NW Bio Announces Scientific Advisory Board.
The SAB members include the following:
Dr. Jerome Galon
https://nwbio.com/nw-bio-announces-scientific-advisory-board/
Evaluate
Monday, 10/17/16 09:42:13 PM
Post : 79561
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=125857107
scotty3371,
The photo is the most valuable ihub photo of the year! (at least for me)
If you do your best you will know why. Just dig a little deeper.
I"ll give you some time. Good luck!
Agreed!
And Prof. Stefaan Van Gool has a bad reputation in his own country. (Belgium)
twitter: update Laura Nuttall.
"Thanks to our amazing #doingitforlaura supporters we’re in Cologne for day 1 of immunotherapy treatment. We’ll be back for 5 days every month for electrohyperthermia & oncolytic virus infusion & when chemo’s finished, dendritic cell vaccine. We wouldn’t be here without you."
Thanks to our amazing #doingitforlaura supporters we’re in Cologne for day 1 of immunotherapy treatment. We’ll be back for 5 days every month for electrohyperthermia & oncolytic virus infusion & when chemo’s finished, dendritic cell vaccine. We wouldn’t be here without you. ❤️
— shitscaredmum (@shitscaredmum) July 29, 2019
Longfellow95,
Thanks!
The picture https://media.licdn.com/dms/image/C4D22AQHUP3pLNCNWig/feedshare-shrink_8192/0?e=1567036800&v=beta&t=fmSZWWX6vyhWvJNOveTGZmsvcGQHPsTQO4seuKQPnkk
was taken about 2 weeks ago.
"Celebrating the journey so far, friends & family of Autolomous."
https://www.linkedin.com/company/autolomous/
Incorporated on 6 February 2019.
https://beta.companieshouse.gov.uk/company/11810723
Today we celebrate my Dad passing the 5-year milestone with GBM. We are thankful for the ongoing support from the CCI Edmonton and Northwest Biotherapeutics, and especially for the hours of caregiving my Mom offers every single day! Go Dad! #GBM #Glioblastoma $NWBO pic.twitter.com/PlypOApbpk
— Kristyn Power, CFA (@KristynPower) July 28, 2019
hmuney,
Thank you! Great news and nice picture! Isn't that Linda Powers behind "Dad Power'?
Today we celebrate my Dad passing the 5-year milestone with GBM. We are thankful for the ongoing support from the CCI Edmonton and Northwest Biotherapeutics, and especially for the hours of caregiving my Mom offers every single day! Go Dad! #GBM #Glioblastoma $NWBO pic.twitter.com/PlypOApbpk
— Kristyn Power, CFA (@KristynPower) July 28, 2019
ECMC
Experimental Cancer Medicine Centres (ECMC) researchers are world-leading scientists and clinicians who drive the discovery, development and testing of new treatments to combat cancer. The funding supports over 200 staff involved in early phase trials and translational research.
P.R. Oct. 28, 2015.